Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 12/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162110 | 0.91 | KDM4C (0.45) | HTR2CHTR2BTAS2R8 | |
| SCHEMBL20162174 | 0.90 | HTR2C (0.43) | HTR2CHTR2BRIPK1TAS2R8 | |
| SCHEMBL20162161 | 0.89 | RIPK1 (0.40) | RIPK1TAS2R8 | |
| SCHEMBL20162126 | 0.88 | RIPK1 (0.39) | RIPK1TAS2R8 | |
| SCHEMBL20162175 | 0.87 | TAS2R8 (0.39) | HTR2CHTR2BRIPK1TAS2R8 | |
| SCHEMBL20162155 | 0.87 | TAS2R8 (0.40) | RIPK1TAS2R8 | |
| SCHEMBL20162162 | 0.86 | TAS2R8 (0.38) | HTR2CHTR2BRIPK1TAS2R8 | |
| SCHEMBL20162116 | 0.85 | TAS2R8 (0.39) | RIPK1TAS2R8 | |
| SCHEMBL20162143 | 0.84 | TAS2R8 (0.37) | HTR2CHTR2BRIPK1TAS2R8 | |
| SCHEMBL20169996 | 0.84 | HTR2C (0.46) | HTR2CHTR2BRIPK1TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | HTR2C 1471/4885HTR2B 2579/4885RIPK1 3470/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | HTR2C 1471/4885HTR2B 2579/4885RIPK1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.